Taken together, these data demonstrate that the therapeutic efficacy of TGFβR2 blockade in TGFβR2‐mutant PDA is a result of the inhibition of the CAF TGFβ‐IL‐6 paracrine signal that drives cancer cell proliferation and inhibits NK cell activity (Appendix Fig S8). This evidence concerns the gene TGFB1 and Patent ductus arteriosus.